Acute liver injury in a Glatopa-treated patient with MS

Sabatino, Joseph J.; Mehta, Neil; Kakar, Sanjay; Zamvil, Scott S.; Cree, Bruce A.C.

doi:10.1212/nxi.0000000000000368

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in the GATE trial in 2017 that included 794 patients, there was no significance difference in hepatobiliary adverse events between the brand name product and biosimilar glatiramer acetate with an event rate that was extremely low for both groups (four total hepatobiliary adverse events) [66]. Despite this, suspected DILI in patients receiving glatiramer acetate biosimilars should be considered when using these new biosimilar agents [67].…”

Section: Quantitative Systems Pharmacology and Dilimentioning

confidence: 99%

Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature

et al. 2021

View full text Add to dashboard Cite

Drug-induced liver injury (DILI) remains an important, yet challenging diagnosis for physicians. Each year, additional drugs are implicated in DILI and this year was no different, with more than 1400 articles published on the subject. This review examines some of the most significant highlights and controversies in DILI-related research over the past year and their implications for clinical practice. Several new drugs were approved by the US Food and Drug Administration including a number of drugs implicated in causing DILI, particularly among the chemotherapeutic classes. The COVID-19 pandemic was also a major focus of attention in 2020 and we discuss some of the notable aspects of COVID-19-related liver injury and its implications for diagnosing DILI. Updates in diagnostic and causality assessments related to DILI such as the Roussel Uclaf Causality Assessment Method are included, mindful that there is still no single biomarker or diagnostic tool to unequivocally diagnose DILI. Glutamate dehydrogenase received renewed attention as being more specific than alanine aminotransferase. There were a few new reports of previously unrecognized hepatotoxins, including immune modulators and novel gene therapy drugs that we highlight. Updates and new developments of previously described hepatotoxins, such as immune checkpoint inhibitors and anti-tuberculosis drugs are reviewed. Finally, novel technologies such as organoid culture systems to better predict DILI preclinically may be coming of age and determinants of hepatocyte loss, such as calculating P ALT are poised to improve our current means of estimating DILI severity and the risk of acute liver failure.

show abstract

Section: Quantitative Systems Pharmacology and Dilimentioning

confidence: 99%